Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients

Acta Pharmacologica Sinica

Volumn 36, Issue 3, 2015, Pages 375-384

  Yin, Ji Ye ^a,b,c   Meng, Xiang Guang ^d   Qian, Chen Yue ^a,b,c   Li, Xiang Ping ^a   Chen, Juan ^a,b,c   Zheng, Yi ^a,b,c   Liu, Rong ^a,b,c   Zhou, Hong Hao ^a,b,c   Liu, Zhao Qian ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Key Laboratory of Pharmacogenetics   (China)

^c Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study   (China)

^d Department of Organ Transplantation   (China)

Author keywords

Chemotherapy toxicity; Chinese NSCLC patients; eIF3a; Lung cancer; Platinum based chemotherapy; Polymorphism; Positive selection

Indexed keywords

ETOPOSIDE; GEMCITABINE; INITIATION FACTOR 3; PACLITAXEL; PEMETREXED; PLATINUM; ANTINEOPLASTIC AGENT; EIF3A PROTEIN, HUMAN; PLATINUM COMPLEX; PLATINUM DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHINESE; CLINICAL TRIAL (TOPIC); DATA BASE; DNA POLYMORPHISM; FEMALE; GASTROINTESTINAL TOXICITY; GENE LOCUS; HAPLOTYPE; HUMAN; HUMAN TISSUE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; NON SMALL CELL LUNG CANCER; POPULATION DIFFERENTIATION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; VOMITING; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHI SQUARE DISTRIBUTION; CHINA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGY; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; ODDS RATIO; PATHOLOGY; PHARMACOGENETICS; PHENOTYPE; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; CHINA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUKARYOTIC INITIATION FACTOR-3; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; PHENOTYPE; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84938527239     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.160     Document Type: Article

References (31)

1. Sonenberg N, Hershey JWB, Mathews MB. Translational control of gene expression. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2000.
2. Yin JY, Dong Z, Liu ZQ, Zhang JT. Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments. Biosci Rep 2011;31:1-15.
3. Dong Z, Zhang JT. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol 2006;59:169-80.
4. Pincheira R, Chen Q, Zhang JT. Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer 2001;84:1520-7.
5. Buratti E, Tisminetzky S, Zotti M, Baralle FE. Functional analysis of the interaction between HCV 5'UTR and putative subunits of eukaryotic translation initiation factor eIF3. Nucleic Acids Res 1998;26:3179-87.
6. Yin JY, Dong ZZ, Liu RY, Chen J, Liu ZQ, Zhang JT. Translational regulation of RPA2 via internal ribosomal entry site and by eIF3a. Carcinogenesis 2013;34:1224-31.
7. Yin JY, Shen J, Dong ZZ, Huang Q, Zhong MZ, Feng DY, et al. Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin Cancer Res 2011;17:4600-9.
8. Xu X, Han L, Duan L, Zhao Y, Yang H, Zhou B, et al. Association between eIF3alpha polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients. Br J Clin Pharmacol 2013;75:516-23.
9. Xu X, Han L, Yang H, Duan L, Zhou B, Zhao Y, et al. The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients. Lung Cancer 2013;79:65-72.
10. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 2004;13:783-97.
11. Chen X, Wang H, Zhou G, Zhang X, Dong X, Zhi L, et al. Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine. Environ Health Perspect 2009;117:1541-8.
12. Ding K, Kullo IJ. Molecular population genetics of PCSK9: a signature of recent positive selection. Pharmacogenet Genomics 2008;18:169-79.
13. Sabeti PC, Reich DE, Higgins JM, Levine HZ, Richter DJ, Schaffner SF, et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 2002;419:832-7.
14. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
15. Lewontin RC. Annotation: the analysis of variance and the analysis of causes. Am J Hum Genet 1974;26:400-11.
16. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 2010;10:564-7.
17. Schulze TG, Chen YS, Akula N, Hennessy K, Badner JA, McInnis MG, et al. Can long-range microsatellite data be used to predict short-range linkage disequilibrium. Hum Mol Genet 2002;11:1363-72.
18. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
19. JG FSTAT, a program to estimate and test gene diversities and fixation indices (version2.9.3). Available from http://www.unil.ch/izea/softwares/fstat.html. Updated from Goudet (1995). 2001.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 2007;81:559-75.
21. International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-96.
22. Akey JM, Zhang G, Zhang K, Jin L, Shriver MD. Interrogating a highdensity SNP map for signatures of natural selection. Genome Res 2002;12:1805-14.
23. Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, et al. Genetic structure of human populations. Science 2002;298:2381-5.
24. Biswas S, Akey JM. Genomic insights into positive selection. Trends Genet 2006;22:437-46.
25. Bamshad M, Wooding SP. Signatures of natural selection in the human genome. Nat Rev Genet 2003;4:99-111.
26. Wang Z, Wang J, Tantoso E, Wang B, Tai AY, Ooi LL, et al. Signatures of recent positive selection at the ATP-binding cassette drug transporter superfamily gene loci. Hum Mol Genet 2007;16:1367-80.
27. Li XP, Yin JY, Wang Y, He H, Li X, Gong WJ, et al. The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumour Biol 2014;35:8259-65.
28. Wang Y, Yin JY, Li XP, Chen J, Qian CY, Zheng Y, et al. The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS One 2014;9:e91967.
29. Wang Y, Li XP, Yin JY, Zhang Y, He H, Qian CY, et al. Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response. Clin Exp Pharmacol Physiol 2014;41:408-15.
30. Chaudhuri J, Chakrabarti A, Maitra U. Biochemical characterization of mammalian translation initiation factor 3 (eIF3). Molecular cloning reveals that p110 subunit is the mammalian homologue of Saccharomyces cerevisiae protein Prt1. J Biol Chem 1997;272:30975-83.
31. Olson JE, Wang X, Goode EL, Pankratz VS, Fredericksen ZS, Vierkant RA, et al. Variation in genes required for normal mitosis and risk of breast cancer. Breast Cancer Res Treat 2010;119:423-30.